<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822003</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 127/07, Amendment 1</org_study_id>
    <nct_id>NCT00822003</nct_id>
  </id_info>
  <brief_title>Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects</brief_title>
  <official_title>Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile Following an Oral Glucose Tolerance Test in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to investigate the pharmacokinetic and pharmacodynamic effects of a
      single dose (2 mg) of oral GLP-1 administered prior to an oral glucose tolerance test (oGTT)
      in 16 healthy males
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Glucagon like peptide-1 (GLP-1) promotes satiety and reduces food intake. GLP-1
      is secreted from intestinal L-cells into the splanchnic circulation, it is (i) subject to
      rapid breakdown and (ii) submitted to a high liver extraction. Highest concentrations of
      GLP-1 are therefore found in the splanchnic blood rather than in the systemic circulation. An
      oral delivery system would mimick the physiological path of endogenous secretion. Objective:
      We aimed to investigate the pharmacokinetic and pharmacodynamic effects of a single dose (2
      mg) of oral GLP-1 administered prior to an oral glucose tolerance test (oGTT) in 16 healthy
      males.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>Glucagon secretion GH release adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Glucose Homeostasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human GLP-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral GLP-1</intervention_name>
    <description>GLP-1 tablet (2mg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control tablet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male subjects

          -  no gastrointestinal or endocrine disorder

        Exclusion Criteria:

          -  females

          -  alcohol or drug abuse

          -  active virus hepatitis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>January 13, 2009</last_update_submitted>
  <last_update_submitted_qc>January 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Beglinger Christoph, Prof. Dr.med.</name_title>
    <organization>University Hospital, Basel, Switzerland</organization>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>insulin</keyword>
  <keyword>glucose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

